Inflarx NV(IFRX)stock report

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company’s product pipeline also includes IFX-2, which is in preclinical development.

Finance:
Market Cap:113M; Shares Outstanding:26.1M; Q3 2019(9/30/19): Cash 62.23M. Loss year 33.5M

EPS and Sales:
https://finance.yahoo.com/quote/IFRX/financials?p=IFRX

Date EPS % last year % last quarter
2018.12.31 -0.45 82.35% -50.00%
2019.3.31 -0.43 10.42% 4.44%
2019.6.30 -0.66 -450.00% -53.49%
2019.9.30 -0.63 -110.00% 4.55%

 

Sale:0

Insider Transactions:
http://insidercow.com/history/company.jsp?company=IFRX&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/IFRX/institutional-ownership/

2019.12.29:
Total institutions: 631,no change
Shares hold: 4539.7k shares. no change
shares% hold: 17.48%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/IFRX/price-targe

Leave a Reply